TY - JOUR
T1 - Transcatheter heart valve explant with infective endocarditis-associated prosthesis failure and outcomes
T2 - the EXPLANT-TAVR international registry
AU - EXPLANT-TAVR Investigators
AU - Marin-Cuartas, Mateo
AU - Tang, Gilbert H.L.
AU - Kiefer, Philipp
AU - Fukuhara, Shinichi
AU - Lange, Rudiger
AU - Harrington, Katherine B.
AU - Saha, Shekhar
AU - Hagl, Christian
AU - Kleiman, Neal S.
AU - Goel, Sachin S.
AU - Kempfert, Joerg
AU - Werner, Paul
AU - Petrossian, George A.
AU - Geirsson, Arnar
AU - Desai, Nimesh D.
AU - Chu, Michael W.A.
AU - Bhadra, Oliver D.
AU - Shults, Christian
AU - Garatti, Andrea
AU - Vincent, Flavien
AU - Grubb, Kendra J.
AU - Goldberg, Joshua B.
AU - Mack, Michael J.
AU - Modine, Thomas
AU - Denti, Paolo
AU - Kaneko, Tsuyoshi
AU - Bapat, Vinayak N.
AU - Reardon, Michael J.
AU - Borger, Michael A.
AU - Zaid, Syed
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/7/21
Y1 - 2024/7/21
N2 - Background and Surgical explantation of transcatheter heart valves (THVs) is rapidly increasing, but there are limited data on patients with Aims THV-associated infective endocarditis (IE). This study aims to assess the outcomes of patients undergoing THV explant for IE. Methods All patients who underwent THV explant between 2011 and 2022 from 44 sites in the EXPLANT-TAVR registry were identified. Patients with IE as the reason for THV explant were compared to those with other mechanisms of bioprosthetic valve dysfunction (BVD). Results A total of 372 patients from the EXPLANT-TAVR registry were included. Among them, 184 (49.5%) patients underwent THV explant due to IE and 188 (50.5%) patients due to BVD. At the index transcatheter aortic valve replacement, patients undergoing THV explant for IE were older (74.3 ± 8.6 vs. 71 ± 10.6 years) and had a lower Society of Thoracic Surgeons risk score [2.6% (1.8–5.0) vs. 3.3% (2.1–5.6), P = .029] compared to patients with BVD. Compared to BVD, IE patients had longer intensive care unit and hospital stays (P < .05) and higher stroke rates at 30 days (8.6% vs. 2.9%, P = .032) and 1 year (16.2% vs. 5.2%, P = .010). Adjusted in-hospital, 30-day, and 1-year mortality was 12.1%, 16.1%, and 33.8%, respectively, for the entire cohort, with no significant differences between groups. Although mortality was numerically higher in IE patients 3 years postsurgery (29.6% for BVD vs. 43.9% for IE), Kaplan–Meier analysis showed no significant differences between groups (P = .16). Conclusions In the EXPLANT-TAVR registry, patients undergoing THV explant for IE had higher 30-day and 1-year stroke rates and longer intensive care unit and hospital stays. Moreover, patients undergoing THV explant for IE had a higher 3-year mortality rate, which did not reach statistical significance given the relatively small sample size of this unique cohort and the reduced number of events.
AB - Background and Surgical explantation of transcatheter heart valves (THVs) is rapidly increasing, but there are limited data on patients with Aims THV-associated infective endocarditis (IE). This study aims to assess the outcomes of patients undergoing THV explant for IE. Methods All patients who underwent THV explant between 2011 and 2022 from 44 sites in the EXPLANT-TAVR registry were identified. Patients with IE as the reason for THV explant were compared to those with other mechanisms of bioprosthetic valve dysfunction (BVD). Results A total of 372 patients from the EXPLANT-TAVR registry were included. Among them, 184 (49.5%) patients underwent THV explant due to IE and 188 (50.5%) patients due to BVD. At the index transcatheter aortic valve replacement, patients undergoing THV explant for IE were older (74.3 ± 8.6 vs. 71 ± 10.6 years) and had a lower Society of Thoracic Surgeons risk score [2.6% (1.8–5.0) vs. 3.3% (2.1–5.6), P = .029] compared to patients with BVD. Compared to BVD, IE patients had longer intensive care unit and hospital stays (P < .05) and higher stroke rates at 30 days (8.6% vs. 2.9%, P = .032) and 1 year (16.2% vs. 5.2%, P = .010). Adjusted in-hospital, 30-day, and 1-year mortality was 12.1%, 16.1%, and 33.8%, respectively, for the entire cohort, with no significant differences between groups. Although mortality was numerically higher in IE patients 3 years postsurgery (29.6% for BVD vs. 43.9% for IE), Kaplan–Meier analysis showed no significant differences between groups (P = .16). Conclusions In the EXPLANT-TAVR registry, patients undergoing THV explant for IE had higher 30-day and 1-year stroke rates and longer intensive care unit and hospital stays. Moreover, patients undergoing THV explant for IE had a higher 3-year mortality rate, which did not reach statistical significance given the relatively small sample size of this unique cohort and the reduced number of events.
KW - Bioprosthetic valve dysfunction
KW - Endocarditis
KW - Surgical aortic valve replacement
KW - TAVR explantation
KW - THV failure
KW - Transcatheter aortic valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85199349567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85199349567&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehae292
DO - 10.1093/eurheartj/ehae292
M3 - Article
C2 - 38820201
AN - SCOPUS:85199349567
SN - 0195-668X
VL - 45
SP - 2519
EP - 2532
JO - European heart journal
JF - European heart journal
IS - 28
ER -